Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Multiplicom's CF and FMF Dx; Enzymatics' Archer FusionPlex Heme; CHLA's RB1 Test

Premium

Multiplicom has launched a next-generation sequencing-based test for cystic fibrosis and plans to launch a test for familial Mediterranean fever in July. The kits will have the CE-IVD marking. Multiplicom has also achieved ISO 13485 accreditation, which certifies the company to design, develop, manufacture, and distribute in vitro molecular diagnostic kits that identify genomic and somatic variants.


Enzymatics has launched its Archer FusionPlex Heme panel, a targeted next-generation sequencing-based assay that detects fusions involving 19 genes associated with hematological malignancies. The assay is based on the company's proprietary anchored multiplex PCR-based enrichment technology.


The Children's Hospital Los Angeles has launched a next-generation sequencing-based retinoblastoma test, RB1 NextGen. The test evaluates germline mutations in the entire RB1 gene.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.